265 related articles for article (PubMed ID: 37116986)
1. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
Messelink MA; den Broeder AA; Marinelli FE; Michgels E; Verschueren P; Aletaha D; Tekstra J; Welsing PMJ
RMD Open; 2023 Apr; 9(2):. PubMed ID: 37116986
[TBL] [Abstract][Full Text] [Related]
2. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
[TBL] [Abstract][Full Text] [Related]
3. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
4. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
Dhaon P; Das SK; Srivastava R; Dhakad U
Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
[TBL] [Abstract][Full Text] [Related]
5. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
6. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
[TBL] [Abstract][Full Text] [Related]
7. A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis.
Janke K; Kiefer C; McGauran N; Richter B; Krause D; Wieseler B
BMC Rheumatol; 2022 Dec; 6(1):82. PubMed ID: 36482451
[TBL] [Abstract][Full Text] [Related]
8. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
Hirano F; Yokoyama W; Yamazaki H; Amano K; Kawakami A; Hayashi T; Tamura N; Yasuda S; Dobashi H; Fujii T; Ito S; Kaneko Y; Matsui T; Okuda Y; Saito K; Suzuki F; Yoshimi R; Sakai R; Koike R; Kohsaka H; Miyasaka N; Harigai M;
Mod Rheumatol; 2017 Sep; 27(5):811-819. PubMed ID: 27919205
[TBL] [Abstract][Full Text] [Related]
9. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
Martins FM; da Silva JA; Santos MJ; Vieira-Sousa E; Duarte C; Santos H; Costa JA; Pimentel-Santos FM; Cunha I; Cunha Miranda L; Nóvoa T; Cruz M; Bernardes M; Araujo D; Pereira Silva JA; Silva JC; Branco JC; Gomes JA; Faustino A; Fonseca JE; Canhão H
Rheumatology (Oxford); 2015 Feb; 54(2):286-91. PubMed ID: 25173347
[TBL] [Abstract][Full Text] [Related]
10. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
[TBL] [Abstract][Full Text] [Related]
11. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.
Gaujoux-Viala C; Mouterde G; Baillet A; Claudepierre P; Fautrel B; Le Loët X; Maillefert JF
Joint Bone Spine; 2012 Mar; 79(2):149-55. PubMed ID: 21680221
[TBL] [Abstract][Full Text] [Related]
12. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis.
Slama IB; Allali F; Lakhdar T; El Kabbaj S; Medrare L; Ngeuleu A; Rkain H; Hajjaj-Hassouni N
BMC Musculoskelet Disord; 2015 Sep; 16():268. PubMed ID: 26420567
[TBL] [Abstract][Full Text] [Related]
13. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
15. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
17. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
Futó G; Somogyi A; Szekanecz Z
Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
[TBL] [Abstract][Full Text] [Related]
18. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
19. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
[TBL] [Abstract][Full Text] [Related]
20. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.
Durán J; Combe B; Niu J; Rincheval N; Gaujoux-Viala C; Felson DT
Rheumatology (Oxford); 2015 Dec; 54(12):2166-70. PubMed ID: 26175470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
